25.31
+0.75(+3.05%)
Currency In USD
| Previous Close | 24.56 |
| Open | 24.49 |
| Day High | 25.89 |
| Day Low | 24.01 |
| 52-Week High | 35.71 |
| 52-Week Low | 16.1 |
| Volume | 2.54M |
| Average Volume | 2.58M |
| Market Cap | 3.2B |
| PE | 70.31 |
| EPS | 0.36 |
| Moving Average 50 Days | 23.12 |
| Moving Average 200 Days | 21.91 |
| Change | 0.75 |
If you invested $1000 in Apellis Pharmaceuticals, Inc. (APLS) since IPO date, it would be worth $1,803.99 as of December 17, 2025 at a share price of $25.31. Whereas If you bought $1000 worth of Apellis Pharmaceuticals, Inc. (APLS) shares 5 years ago, it would be worth $475.13 as of December 17, 2025 at a share price of $25.31.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
GlobeNewswire Inc.
Dec 03, 2025 10:05 PM GMT
Robust and clinically meaningful benefits across all three key markers of disease – 68% reduction in proteinuria, stabilization of kidney function, and substantial clearance of C3 depositsConsistent results across adolescent and adult patients with C
Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years
GlobeNewswire Inc.
Nov 12, 2025 12:00 PM GMT
WALTHAM, Mass., Nov. 12, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced data from a post hoc analysis of the GALE extension study following five years of continuous treatment with SYFOVRE® (pegcetacoplan injec
Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference
GlobeNewswire Inc.
Nov 05, 2025 12:00 PM GMT
WALTHAM, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Stifel 2025 Healthcare Conference on Wednesday, November 12, 2025 at 2:40 p.m. ET. The live conferen